Scientists have reported the discovery of a factor capable of lowering levels of tau in the brain. Tau is a protein high on the list of potential villains in Alzheimer’s disease. The study, “Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model,” was published in the journal Neuron. The…
News
The mutated gene, as well as the position of the mutation within a gene, impact the kind of symptoms patients with dominantly inherited Alzheimer’s disease develop, according to new research. These findings also underscored the notion that familial Alzheimer’s is a highly variable condition, making genetic testing a crucial component…
Patients with inherited forms of Alzheimer’s disease have neurological symptoms other than memory loss, suggesting that physicians need watch for less typical symptoms when suspecting familial Alzheimer’s in a patient. While the study also found atypical symptoms can differ among patient groups, a comment suggested that such differences partly reflect the large…
Researchers working in a mice reported that an experimental drug, NTRX-07, may treat Alzheimer’s by targeting a potential cause — it was seen to ease brain inflammation in the animals by restoring the brain’s ability to remove clumps of the beta-amyloid protein that is a hallmark of the disease. The excessive…
Low-calorie diets are a known benefit for the overall health of the body, but the exact mechanisms underlying this effect remain elusive. Now, a study published in the journal Aging Cell, has shown that low-calorie intake increases neurons’ capacity to neutralize excessive levels of calcium, which contribute to neuronal damage…
Alzheimer’s-related Tau Protein as Potential New Biomarker for Teens with Early-onset Psychosis
Tau, a protein already linked to Alzheimer’s disease, can be traced in greater concentrations in the blood plasma levels of under-age children with early onset psychosis (EOP), according to a recent study. The study was included at this year’s International Early Psychosis Association (IEPA) meeting Oct. 20-22 in Milan,…
Roobirk and Antidote, two startup companies that work to empower people living with Alzheimer’s disease have entered a partnership with Galaxy, an online portal to initiatives that facilitate patient participation in Alzheimer’s research. More than 80% of clinical studies overall are delayed or closed because not enough patients meet enrollment requirements.
A treatment that uses microscopic droplets of fat – called nanoliposomes – to carry drugs to the brain has been used effectively to target cancer cells. Now the technique has shown promise in restoring memory loss in mice models of Alzheimer’s disease, according to a new study funded by the Alzheimer’s…
Most National Alzheimer’s Project Studies Not Looking to Show Clinical Benefit, Scientists Argue
Two physicians — one at the University of Pennsylvania’s Perelman School of Medicine and the other with the University of Michigan — argue in a recent opinion piece that the National Alzheimer Project Act (NAPA), as it now stands, has resulted in potential treatments for Alzheimer’s disease being tested without a…
A technique using light intensity to detect explosive residue in homemade bombs, also known as improvised explosive devices (IEDs), is now being used by researchers from the University of Adelaide in South Australia to identify vitamins in blood that are linked to Alzheimer’s disease and dementia. Vitamin B12 is…
Recent Posts
- FDA decision on AXS-05 for Alzheimer’s agitation expected April 30 January 6, 2026
- Oral semaglutide fails to slow Alzheimer’s in pair of clinical trials December 2, 2025
- Canada gives conditional OK to early Alzheimer’s drug Leqembi November 4, 2025
- Kisunla approval offers new option to treat early Alzheimer’s in Europe October 3, 2025
- Guest Voice: A journey through loss, love, and remembrance October 2, 2025